UNCY on Nasdaq
Unicycive Therapeutics, Inc.
American pharmaceutical preparations company based in Los Altos. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Karuna Therapeutics, Polomar Health Services, Inc. or Summit Therapeutics, or pick any stock.
- TickerUNCY on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersMountain View, California1
- Incorporated inDE2
- Business address1975 W. El Camino Real, Suite 204, Mountain View, Ca 940402
- Filer category, Emerging growth company2
- Legal formCorporation
See how the biggest companies compare on our leaderboards
2,100 highest prescribers are responsible for half of the prescriptions written for PLTs annually.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2023
Where the money goes
Where each dollar of revenue went, fiscal 2023
- Research and development99¢$12.9M
- Interest1¢$82.0K
Out of $675.0K in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.10
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $9.1M | $20.0M |
| General and administrative | $20.4M | $12.1M |
| Total operating expenses | $29.5M | $32.1M |
| Loss from operations | -$29.5M | -$32.1M |
| Interest income | $1.0M | $1.3M |
| Interest expense | -$71.0K | -$71.0K |
| Change in fair value of warrant liability | $2.0M | -$5.8M |
| Total other income (expenses) | $3.0M | -$4.6M |
| Net loss | -$26.6M | -$36.7M |
| Unrealized loss on marketable securities, net | -$1.0K | |
| Net comprehensive loss | -$26.6M | -$36.7M |
| Dividend to Series B-1 preferred stockholders | -$1.1M | |
| Net loss attributable to common stockholders | -$26.6M | -$37.8M |
| Net loss per share attributable to common stockholders, basic (in Dollars per share) | -$1.67 | -$5.65 |
| Net loss per share attributable to common stockholders, diluted (in Dollars per share) | -$1.67 | -$5.65 |
| Weighted-average shares outstanding used in computing net loss per share, basic (in Shares) | 15.9M shares | 6.7M shares |
| Weighted-average shares outstanding used in computing net loss per share, diluted (in Shares) | 15.9M shares | 6.7M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.10
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $29.2M | $26.1M | |
| Prepaid expenses and other current assets | $7.7M | $4.8M | |
| Marketable securities | $12.1M | ||
| Total current assets | $49.0M | $30.9M | |
| Right of use asset, net | $108.0K | $645.0K | |
| Property and equipment, net | $66.0K | $75.0K | |
| Total assets | $49.1M | $31.7M | |
| Accounts payable | $383.0K | $1.1M | |
| Accrued liabilities | $1.5M | $3.6M | |
| Warrant liability | $16.9M | $18.9M | |
| Operating lease liability - current | $117.0K | $564.0K | |
| Total current liabilities | $18.9M | $24.1M | |
| Operating lease liability long term | $117.0K | ||
| Total liabilities | $18.9M | $24.2M | |
| Common stock, $0.001 par value per share 400,000,000 shares authorized at December 31, 2024, and December 31, 2025; 11,384,236 and 22,114,245 shares issued and outstanding at December 31, 2024, and December 31, 2025, respectively | $22.0K | $11.0K | |
| Accumulated other comprehensive loss | -$1.0K | ||
| Additional paid-in capital | $158.0M | $108.7M | |
| Accumulated deficit | -$127.8M | -$101.3M | |
| Total stockholders equity | $30.2M | $7.4M | -$3.8M |
| Total liabilities and stockholders equity | $49.1M | $31.7M | |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in Shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares outstanding (in Shares) | 0 shares | 0 shares | |
| Preferred stock, shares issued (in Shares) | 0 shares | 0 shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 400.0M shares | 400.0M shares | |
| Common stock, shares issued (in Shares) | 22.1M shares | 11.4M shares | |
| Common stock, shares outstanding (in Shares) | 22.1M shares | 11.4M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $29.2M | $26.1M | |
| Prepaid expenses and other current assets | $7.7M | $4.8M | |
| Marketable securities | $12.1M | ||
| Total current assets | $49.0M | $30.9M | |
| Right of use asset, net | $108.0K | $645.0K | |
| Property and equipment, net | $66.0K | $75.0K | |
| Total assets | $49.1M | $31.7M | |
| Accounts payable | $383.0K | $1.1M | |
| Accrued liabilities | $1.5M | $3.6M | |
| Warrant liability | $16.9M | $18.9M | |
| Operating lease liability - current | $117.0K | $564.0K | |
| Total current liabilities | $18.9M | $24.1M | |
| Operating lease liability long term | $117.0K | ||
| Total liabilities | $18.9M | $24.2M | |
| Common stock, $0.001 par value per share 400,000,000 shares authorized at December 31, 2024, and December 31, 2025; 11,384,236 and 22,114,245 shares issued and outstanding at December 31, 2024, and December 31, 2025, respectively | $22.0K | $11.0K | |
| Accumulated other comprehensive loss | -$1.0K | ||
| Additional paid-in capital | $158.0M | $108.7M | |
| Accumulated deficit | -$127.8M | -$101.3M | |
| Total stockholders equity | $30.2M | $7.4M | -$3.8M |
| Total liabilities and stockholders equity | $49.1M | $31.7M | |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in Shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares outstanding (in Shares) | 0 shares | 0 shares | |
| Preferred stock, shares issued (in Shares) | 0 shares | 0 shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 400.0M shares | 400.0M shares | |
| Common stock, shares issued (in Shares) | 22.1M shares | 11.4M shares | |
| Common stock, shares outstanding (in Shares) | 22.1M shares | 11.4M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.10
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$26.6M | -$36.7M |
| Depreciation expense | $34.0K | $22.0K |
| Stock-based compensation expense | $2.6M | $2.4M |
| Change in fair value of warrant liability | -$2.0M | $5.8M |
| Amortization of operating lease right of use asset | $538.0K | $406.0K |
| Prepaid expense and other current assets | -$2.9M | -$820.0K |
| Accounts payable and accrued liabilities | -$2.5M | $790.0K |
| Operating lease liability | -$565.0K | -$397.0K |
| Net cash used in operating activities | -$31.3M | -$28.6M |
| Purchases of marketable securities | -$12.1M | |
| Purchases of property and equipment | -$24.0K | -$72.0K |
| Net cash used in investing activities | -$12.1M | -$72.0K |
| Gross proceeds from secondary public offering | $46.6M | $683.0K |
| Commissions paid on secondary public offering | -$1.4M | |
| Deferred cost of at the market offering | -$160.0K | |
| Payments on financed insurance policies | -$212.0K | -$527.0K |
| Issuance costs related to issuance of Series B-1 preferred stock | -$3.8M | |
| Proceeds from issuance of Series B-1 preferred stock | $50.0M | |
| Proceeds from exercise of warrants | $1.5M | |
| Dividends on preferred stock | -$1.1M | |
| Net cash provided by financing activities | $46.5M | $45.1M |
| Net increase in cash and cash equivalents | $3.1M | $16.4M |
| Issuance of Series B-2 preferred stock and common stock upon conversion of Series B-1 preferred stock | $46.2M | |
| Deferred insurance charges included in prepaid expenses and other current assets | $332.0K | $267.0K |
| Cash paid for interest | $12.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Unicycive Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Board members and other officers (6)
- EVP of Corporate StrategyDouglas Jermasek Nov 23, 2022 to now11
- EVP, Pharma and Business OpsPramod Gupta Jul 12, 2021 to now12
- Board memberGaurav Aggarwal Mar 8, 2023 to now13
- Board memberSara Kenkare-Mitra Sep 7, 2023 to now14
- Board memberBrigitte Schiller Jul 12, 2021 to Apr 18, 202315
- Board memberSandeep Laumas Jul 12, 2021 to now16
Named in SEC Form D filings
People the company listed in its private-offering notices.
Filings
254 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 70 major events, 59 insider forms, 50 large holders, 2 private raises, 53 other. The latest 20:
- Oct 1, 20263 EDGAR
- Sep 29, 20268-K CURRENT REPORT EDGAR
- Sep 28, 20268-K CURRENT REPORT EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 12, 20268-K CURRENT REPORT EDGAR
- Aug 12, 202610-Q QUARTERLY REPORT EDGAR
- Jul 30, 2026SCHEDULE 13G EDGAR
- Jul 28, 20264/A EDGAR
- Jul 28, 20264/A EDGAR
- Jul 8, 2026SCHEDULE 13G/A EDGAR
- Jul 2, 20268-K CURRENT REPORT EDGAR
- Jul 1, 2026144 EDGAR
- Jun 22, 2026DEFA14A CURRENT REPORT EDGAR
- Jun 22, 20268-K CURRENT REPORT EDGAR
- Jun 15, 2026EFFECT EDGAR
- Jun 15, 20264/A EDGAR
- Jun 15, 20264/A EDGAR
- Jun 15, 20264/A EDGAR
- Jun 15, 20264/A EDGAR
The 254 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 16, 2022 | Schiller BrigitteDirector | Buy | 15,000 | $0.83 | $12.4K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Nantahala Capital Management, LLCSCHEDULE 13G/A, 10 filings Feb 14, 2022 to Aug 14, 202618
- Vivo Opportunity Fund Holdings, L.P.SCHEDULE 13G/A, 5 filings Jul 14, 2023 to Aug 14, 202619
- BlackRockSCHEDULE 13G, 1 filing Jul 30, 202620
- INTEGRATED CORE STRATEGIES (US) LLCSCHEDULE 13G/A, 2 filings Jan 23, 2026 to Jul 8, 202621
- RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13G/A, 8 filings Jul 6, 2023 to May 15, 202622
- Octagon Capital Advisors LPSCHEDULE 13G/A, 4 filings Oct 11, 2024 to Feb 10, 202623
- GREAT POINT PARTNERS LLCSCHEDULE 13G/A, 5 filings Jul 18, 2024 to Nov 14, 202524
- BIOTECHNOLOGY VALUE FUND L PSCHEDULE 13G/A, 3 filings Jul 6, 2023 to Aug 14, 202525
- Walleye Capital LLCSCHEDULE 13G/A, 2 filings Nov 13, 2024 to Feb 6, 202526
- Nantahala Capital Partners Limited PartnershipSCHEDULE 13G/A, 3 filings Feb 5, 2024 to Dec 20, 202427
- Logos Global Management LPSC 13G/A, 2 filings Jan 22, 2024 to Nov 14, 202428
- ARMISTICE CAPITAL, LLCSC 13G/A, 3 filings Feb 15, 2022 to Feb 14, 202429
- Altium Capital Management LLCSC 13G/A, 1 filing Feb 14, 202230
- Rosalind Advisors, Inc.SC 13G/A, 1 filing Jan 20, 202231
Money raised
Private offerings the company reported to the SEC on Form D.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 80. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 2,802,894 | $13.1M | 0.4% | +1,863,692 |
| BlackRock, Inc. | 1,413,381 | $6.6M | 0.0% | +1,377,478 |
| Vanguard Capital Management LLC | 1,071,481 | $5.0M | 0.0% | +260,051 |
| Octagon Capital Advisors LP | 1,000,000 | $4.7M | 0.4% | No change |
| Geode Capital Management, LLC | 564,019 | $2.6M | 0.0% | +360,275 |
| Vivo Capital, LLC | 550,000 | $2.6M | 0.2% | −1,239,916 |
| Marshall Wace, Llp | 547,862 | $2.6M | 0.0% | +392,924 |
| Logos Global Management LP | 473,563 | $2.2M | 0.1% | No change |
| State Street Corp | 450,162 | $2.1M | 0.0% | +370,135 |
| Diametric Capital, LP | 374,132 | $1.8M | 0.2% | +293,770 |
| J. Goldman & Co LP | 327,345 | $1.5M | 0.1% | New |
| Diadema Partners LP | 303,676 | $1.4M | 0.5% | +197,593 |
| Millennium Management LLC | 271,456 | $1.3M | 0.0% | −1,127,892 |
| Dauntless Investment Group, LLC | 214,000 | $1.0M | 1.7% | +66,913 |
| Citigroup Inc | 182,654 | $856.6K | 0.0% | +182,653 |
| Northern Trust Corp | 181,930 | $853.3K | 0.0% | +145,993 |
| Vanguard Portfolio Management LLC | 169,196 | $793.5K | 0.0% | New |
| Susquehanna International Group, Llp | 160,039 | $750.6K | 0.0% | −39,180 |
| Jump Financial, LLC | 153,000 | $717.6K | 0.0% | New |
| Vanguard Fiduciary Trust Co | 148,965 | $698.6K | 0.0% | +47,891 |
| Goldman Sachs Group Inc | 145,304 | $681.5K | 0.0% | +118,211 |
| Dimensional Fund Advisors LP | 143,052 | $678.0K | 0.0% | No change |
| Seven Fleet Capital Management LP | 103,400 | $521.1K | 0.1% | +47,700 |
| Caption Management, LLC | 110,000 | $515.9K | 0.0% | New |
| Morgan Stanley | 109,645 | $514.2K | 0.0% | −78,537 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARGaurav Aggarwal, Board member
- 14SEC EDGARSara Kenkare-Mitra, Board member
- 15SEC EDGARBrigitte Schiller, Board member
- 16SEC EDGARSandeep Laumas, Board member
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31